H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $5 from $25 and keeps a Buy rating on the shares after the company reported final data from the Phase 2 ASPEN-06 study. The firm is encouraged by the data but lowered ALX’s peak penetration rate estimate in head and neck cancer to 10% from 25% given the evolving competitive landscape.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO: